Hudock Inc’s Atossa Therapeutics ATOS Stock Holding History

Hudock Inc’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-33	Closed	–	–	751
2022 Q2	$0	Hold	33	–	–	﹤0.01%	745
2022 Q1	$0	Hold	33	–	–	﹤0.01%	747
2021 Q4	$0	Hold	33	–	–	﹤0.01%	762
2021 Q3	$1K	Buy	+33	New	+$1.92K	﹤0.01%	789

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Hudock Inc's ATOS Position: Q3 2022 in Review

Hudock Inc sold out of Atossa Therapeutics (ATOS) in Q3 2022, closing a stake of 33 shares.

Hudock Inc first reported a position in ATOS in Q3 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 56 funds tracked by Wall St. Rank hold ATOS as of Q3 2022.

Hudock Inc reported no remaining Atossa Therapeutics position as of Q3 2022 after selling out during the quarter.
Hudock Inc sold 33 Atossa Therapeutics shares in Q3 2022.
Hudock Inc first reported a position in Atossa Therapeutics in Q3 2021 and held it in 4 quarters.
Hudock Inc's Atossa Therapeutics position peaked at $1K in Q3 2021.
56 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2022.

Based on Hudock Inc's 13F filing for Q3 2022, filed 2 Nov 2022.